Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Kwon N, Park"'
Publikováno v:
Expert Review of Pharmacoeconomics & Outcomes Research. 23:55-61
Non-small cell lung cancer (NSCLC) positive for programmed cell death ligand 1 (PD-L1) may be eligible for targeted immunotherapies. Literature does not currently estimate direct costs associated with this population. We aimed to identify the total d